Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:CLSNOTCMKTS:IGXTOTCMKTS:NMUSNASDAQ:SEEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.22-0.4%$1.22$0.59▼$11.12$86.18M0.221.49 million shs116,061 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsIGXTIntelGenx Technologies$0.16-3.5%$0.16$0.09▼$0.22$28.63M2.4385,193 shs398,613 shsNMUSNemus Bioscience$0.65-9.5%$10.59$0.05▼$0.74$87.04M-0.04377,395 shs1.00 million shsSEELSeelos Therapeutics$0.32-2.0%$0.74$0.32▼$49.80$4.39M1.88424,387 shs166,893 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%0.00%+6.09%-3.17%-86.56%CLSNImunon0.00%0.00%0.00%0.00%0.00%IGXTIntelGenx Technologies-3.53%-8.94%+2.42%+13.03%-5.53%NMUSNemus Bioscience0.00%-94.93%-94.58%-71.74%+4,477.46%SEELSeelos Therapeutics+0.43%-15.06%-35.45%-69.71%-98.44%He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics1.4806 of 5 stars3.13.00.00.00.01.71.3CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.9116 of 5 stars3.24.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,731.28% UpsideCLSNImunonN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0021,727.25% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.76N/AN/A$2.22 per share0.55CLSNImunon$500K0.00N/AN/A$9.66 per share0.00IGXTIntelGenx Technologies$1.04M27.53N/AN/A($0.07) per share-2.34NMUSNemus BioscienceN/AN/AN/AN/A($0.12) per shareN/ASEELSeelos Therapeutics$2.20M1.99N/AN/A($3.42) per share-0.09Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/ANMUSNemus Bioscience-$19.19MN/A0.00∞N/AN/AN/A-924.42%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)Latest ACRS, NMUS, CLSN, IGXT, and SEEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million 2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/ANMUSNemus BioscienceN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16CLSNImunon0.136.526.52IGXTIntelGenx TechnologiesN/A0.410.40NMUSNemus BioscienceN/A0.120.12SEELSeelos TherapeuticsN/A0.140.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CLSNImunon12.97%IGXTIntelGenx TechnologiesN/ANMUSNemus BioscienceN/ASEELSeelos Therapeutics23.37%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%CLSNImunon4.66%IGXTIntelGenx Technologies62.67%NMUSNemus Bioscience2.70%SEELSeelos Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableCLSNImunon277.10 million6.77 millionOptionableIGXTIntelGenx Technologies4174.66 million65.20 millionNot OptionableNMUSNemus BioscienceN/A133.91 millionN/ANot OptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableACRS, NMUS, CLSN, IGXT, and SEEL HeadlinesSourceHeadlineInfusion therapy SLS-005 fails to slow ALS progression in trialalsnewstoday.com - April 4 at 11:49 PMSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023investorplace.com - March 22 at 3:12 PMALS trial flops but Seelos sees potential for efficacythepharmaletter.com - March 21 at 6:27 PMSLS-005 may slow ALS progression for patients not on Relyvrio: Studyalsnewstoday.com - March 20 at 5:39 PMOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Resultsmarkets.businessinsider.com - March 20 at 5:39 PMSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpointsmarkets.businessinsider.com - March 19 at 10:34 PMSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpointsmarketwatch.com - March 19 at 10:34 PMNasdaq Down 100 Points; US Housing Starts Surge In Februarymarkets.businessinsider.com - March 19 at 5:34 PMCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Whymsn.com - March 19 at 5:34 PMSeelos says ALS treatment fails in mid-stage studyreuters.com - March 19 at 5:34 PMUPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage studyfinance.yahoo.com - March 19 at 5:34 PMSeelos falls as lead drug fails in ALS trialmsn.com - March 19 at 9:35 AMSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)prnewswire.com - March 19 at 8:15 AMFrom LSD to healing minds: Where are we standing in psychedelic drug development?labiotech.eu - March 13 at 1:26 PMSeelos Therapeutics files patent for treatment of neurodegenerative diseases using viral vectors encoding peptidespharmaceutical-technology.com - March 6 at 7:00 PMSeelos Therapeutics Inc.thestreet.com - February 9 at 11:53 AMSeelos Therapeutics, Inc. (SEEL)ca.finance.yahoo.com - February 1 at 12:51 PMSeelos Therapeutics Issues Common Warrants to Investorsmsn.com - January 31 at 3:52 PMSeelos Therapeutics Strikes $4M Direct Offering Dealmsn.com - January 31 at 10:18 AMSeelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of Sharesmarkets.businessinsider.com - January 26 at 9:42 PMSeelos Therapeutics Shares Hit 52-Week Low After Direct Offering Pricesmarketwatch.com - January 26 at 9:42 PMSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - January 26 at 9:42 PMSeelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDAmarkets.businessinsider.com - January 22 at 10:13 AMSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002finance.yahoo.com - January 22 at 10:13 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.IntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Nemus BioscienceOTCMKTS:NMUSNemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.